Myasthenia gravis

1,273,368views

Myasthenia gravis

Michael Kallsen

Michael Kallsen

Autosomal trisomies: Pathology review
Down syndrome (Trisomy 21)
Inheritance patterns
DNA damage and repair
DNA replication
Free radicals and cellular injury
Cell cycle
Selective permeability of the cell membrane
Colorectal polyps and cancer: Pathology review
Endometrial hyperplasia and cancer: Clinical
Lung cancer
Metaplasia and dysplasia
Oral cancer
Testicular cancer
Breast cancer: Pathology review
Hypertension: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Angina pectoris
Aortic valve disease
Arterial disease
Asthma
Atrial septal defect
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Coarctation of the aorta
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Heart failure
Mitral valve disease
Myocardial infarction
Patent ductus arteriosus
Pericarditis and pericardial effusion
Peripheral artery disease
Pleural effusion
Pneumonia
Pulmonary edema
Restrictive lung diseases
Shock
Stroke volume, ejection fraction, and cardiac output
Tetralogy of Fallot
Dementia: Pathology review
Anxiety disorders: Clinical
Arteriovenous malformation
Bipolar and related disorders
Cauda equina syndrome
Cranial nerves
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Myasthenia gravis
Panic disorder
Parkinson disease
Stroke: Clinical
Alzheimer disease
Diabetes mellitus: Pathology review
Abnormal uterine bleeding: Clinical
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hyperthyroidism: Pathology review
Hypothyroidism: Pathology review
Hypothyroidism
Neisseria gonorrhoeae
Pelvic inflammatory disease
Polycystic ovary syndrome
Primary adrenal insufficiency
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Testosterone
Thyroid hormones
Benign prostatic hyperplasia
Anemia of chronic disease
Chronic leukemia
Coagulation disorders: Pathology review
Disseminated intravascular coagulation
Factor V Leiden
Hemophilia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Hypocalcemia
Hypokalemia
Inflammation
Innate immune system
Introduction to the immune system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Acute cholecystitis
Acute pancreatitis
Acute pyelonephritis
Alcohol-associated liver disease
Appendicitis
Autoimmune hepatitis
Biliary colic
Bowel obstruction
Celiac disease
Chronic cholecystitis
Chronic pyelonephritis
Chronic pancreatitis
Cirrhosis
Congenital disorders: Clinical
Crohn disease
Gastroesophageal reflux disease (GERD)
Irritable bowel syndrome
Lower urinary tract infection
Nephrotic syndromes: Pathology review
Peptic ulcer
Renal failure: Pathology review
Ulcerative colitis
Urinary tract infections: Pathology review
Viral hepatitis
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Skin cancer
Varicella zoster virus

Flashcards

Myasthenia gravis

0 of 12 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 5 complete

Start
A 40-year-old woman begins complaining of dyspnea while recovering in the post-anesthesia care unit. Earlier in the day, the patient underwent a laparoscopic cholecystectomy for treatment of symptomatic gallstones. Past medical history is unremarkable. Her temperature is 37.7°C (99.9°F), pulse is 93/min, respiratory rate is 24/min and blood pressure is 125/72 mmHg. Physical examination shows the patient in distress with shallow breaths, using accessory muscles. In addition, the patient is observed to have drooping of the eyelids and corners of the mouth bilaterally. Pupils are 3 cm bilaterally and reactive to light. An arterial blood gas measurement reveals the following findings:  

 Laboratory Value  Result  Reference Range 
 pH  7.31  7.35-7.45 
 PaCO2  56 mmHg  33-45 mmHg 
 PaO2  71 mmHg  75-105 mmHg 
 Bicarbonate  25 mmol/L  22-28 mmol/L 
   
The patient’s condition improves with administration of edrophonium chloride. Which of the following best describes the cause of this patient’s condition? 

Transcript

Watch video only

Myasthenia gravis comes from the Greek word ‘myasthenia’, meaning muscle weakness; and the Latin word ‘gravis’, meaning severe. So, myasthenia gravis is an autoimmune condition that causes serious muscle weakness.

First, let's focus on physiology and how muscles normally work. Whether you’re reaching for a slice of pizza or sinking that perfect shot in basketball, it all starts in the brain. The upper motor neuron of the cerebral cortex fires an action potential down the spinal cord to activate lower motor neurons. Next, lower motor neurons pick up these signals and pass them along their axons toward terminal branches and axon terminals, all the way to skeletal muscle fibers.

This communication site between the lower motor neuron and the skeletal muscle fiber is known as the neuromuscular junction, which consists of three main parts. First, there’s the presynaptic membrane, which is the axon terminal of the lower motor neuron packed with acetylcholine vesicles. Acetylcholine is actually the neurotransmitter that enables muscle contraction. Next, there’s the postsynaptic membrane, which is the membrane of the skeletal muscle fiber, rich in nicotinic acetylcholine receptors.

Finally, this tiny space between two membranes is called the synaptic cleft and contains the enzyme acetylcholine esterase.

Now, the arrival of the action potential at the axon terminal triggers the opening of voltage-gated calcium channels in the presynaptic membrane, allowing calcium ions to rush in. This triggers the acetylcholine vesicles to fuse with the presynaptic membrane and release acetylcholine into the synaptic cleft. Once inside the cleft, acetylcholine moves across to bind nicotinic acetylcholine receptors on the postsynaptic membrane. Eventually, this binding triggers the muscle cell to depolarize, setting off a chain of intracellular events that lead to contraction. Once the contraction is over, acetylcholine is broken down by acetylcholine esterase, allowing the muscle to relax and prepare for the next signal.

In myasthenia gravis, the immune system produces antibodies that disrupt the normal function of nicotinic acetylcholine receptors. Now, there are three types of autoantibodies. First, we have blocking antibodies, which bind and block acetylcholine receptors, so acetylcholine can’t activate them. Next, there are binding antibodies, which bind the receptors and activate the complement system, eventually destroying them. Finally, the third type includes modulating antibodies, which bind the receptors and trigger the muscle cell to pull the entire receptor inside.

As more receptors are blocked, destroyed, or removed from the postsynaptic membrane, it becomes harder for muscles to receive signals, leading to muscle weakness.

But that's not all. Sometimes, the immune system does not directly attack the acetylcholine receptors. Instead, it targets other important proteins that help neuromuscular junctions work properly, like Muscle Specific Kinase and Lipoprotein Related Protein 4. When they are disrupted, the connection between nerves and muscles becomes unstable or weak, making it even harder for signals to reach the muscle and causing further muscle weakness.

Now, several risk factors contribute to myasthenia gravis, including thymic abnormalities and genetics. In thymic hyperplasia, the thymus enlarges and forms reactive B-cell follicles that produce autoantibodies. Next up is thymoma, which is a tumor that arises from the epithelial cells of the thymus. Both conditions can cause the thymus to misguide the immune system into attacking acetylcholine receptors.

Next up are genetic factors. Certain HLA subtypes, which are genes that help control the immune system, can make someone more likely to develop autoimmune conditions like myasthenia gravis. Moreover, myasthenia gravis often shows up alongside other autoimmune diseases, such as thyroiditis, lupus, or rheumatoid arthritis.

Now, moving to clinical manifestations. As the immune system blocks, destroys or removes receptors from the postsynaptic membrane, muscles have a hard time receiving signals. Ultimately this leads to muscle weakness and fatigue, which is more pronounced in the proximal muscles.

Remember when you were a kid and spent the whole day in the backyard shooting basketballs? Imagine that after a few throws your muscles start to feel weak. You’d have to stop and rest before you could keep playing. Well, that’s what it’s like for someone with myasthenia gravis. Their muscles get tired quickly, even with simple things like brushing their teeth or combing their hair.

Key Takeaways

Myasthenia gravis is an autoimmune disease, specifically a type II hypersensitivity disorder, which is characterized by autoantibodies against nicotinic acetylcholine receptors on the surface of muscle cells.

The antibodies block the receptors which means the signal to contract isn't received. Those antibodies also activate the complement pathway which leads to muscle cell destruction.

Symptoms can range from mild to severe and may include drooping eyelids, difficulty speaking or swallowing, and muscle weakness in the arms and legs. Treatment involves immunosuppressive drugs like prednisolone, and acetylcholinesterase inhibitors like neostigmine. The purpose is to reduce the immune system's attack on the muscle and to increase muscle strength.

Sources

  1. "Robbins & Kumar Basic Pathology. Available from: ClinicalKey Student, (11th Edition). " Elsevier Limited (UK) (2022. Page 718-720 )
  2. "Conn's Current Therapy 2025. Available from: ClinicalKey Student" Elsevier Limited (UK) (2024. Page 806-811 )
  3. "Crush Step 1 E-Book. Available from: ClinicalKey Student, (3rd Edition)" Elsevier Limited (UK) (2023. Page 461-471 )